These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 2159863)

  • 21. A kinetic study of NMC-A beta-lactamase, an Ambler class A carbapenemase also hydrolyzing cephamycins.
    Mariotte-Boyer S; Nicolas-Chanoine MH; Labia R
    FEMS Microbiol Lett; 1996 Sep; 143(1):29-33. PubMed ID: 8807798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protection of piperacillin and ticarcillin from beta-lactamase hydrolysis by tazobactam (YTR-830) and clavulanic acid.
    Diver JM; Thornber D; Wise R
    J Antimicrob Chemother; 1989 Jul; 24(1):89-92. PubMed ID: 2550415
    [No Abstract]   [Full Text] [Related]  

  • 23. Synergistic activity of mecillinam in combination with the beta-lactamase inhibitors clavulanic acid and sulbactam.
    Neu HC
    Antimicrob Agents Chemother; 1982 Sep; 22(3):518-9. PubMed ID: 6291454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of pH on activities of novel beta-lactamases and beta-lactamase inhibitors against these beta-lactamases.
    Ohsuka S; Arakawa Y; Horii T; Ito H; Ohta M
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1856-8. PubMed ID: 7486932
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of a beta-lactamase produced by Pseudomonas paucimobilis.
    Corkill JE; Hart CA; McLennan AG; Aspinall S
    J Gen Microbiol; 1991 Jun; 137(6):1425-9. PubMed ID: 1655952
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relative efficacy of tazobactam, sulbactam and clavulanic acid in enhancing the potency of ampicillin against clinical isolates of Enterobacteriaceae.
    Pfaller M; Barry A; Fuchs P; Gerlach E; Hardy D; McLaughlin J
    Eur J Clin Microbiol Infect Dis; 1993 Mar; 12(3):200-5. PubMed ID: 8389705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
    Nomura S; Hanaki H; Nagayama A
    J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
    [TBL] [Abstract][Full Text] [Related]  

  • 28. OHIO-1 beta-lactamase resistant to mechanism-based inactivators.
    Bonomo RA; Currie-McCumber C; Shlaes DM
    FEMS Microbiol Lett; 1992 Apr; 71(1):79-82. PubMed ID: 1320587
    [No Abstract]   [Full Text] [Related]  

  • 29. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors.
    Qadri SM; Ueno Y; Cunha BA
    Chemotherapy; 1996; 42(5):334-42. PubMed ID: 8874972
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evolution of beta-lactamase inhibitors.
    Rolinson GN
    Rev Infect Dis; 1991; 13 Suppl 9():S727-32. PubMed ID: 1656513
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Timentin and beta-lactamases.
    Labia R; Morand A; Péduzzi J
    J Antimicrob Chemother; 1986 May; 17 Suppl C():17-26. PubMed ID: 3487538
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergy of clavulanic acid, sulbactam and tazobactam (YTR 830) with amoxycillin against fifty beta-lactamase-producing strains of Haemophilus influenzae.
    Simonet M; Moittie D; Philippon A; Descamps P; Veron M
    J Antimicrob Chemother; 1989 May; 23(5):798-800. PubMed ID: 2547748
    [No Abstract]   [Full Text] [Related]  

  • 33. Antibacterial characteristics of YTR 830, a sulfone beta-lactamase inhibitor, compared with those of clavulanic acid and sulbactam.
    Moosdeen F; Williams JD; Yamabe S
    Antimicrob Agents Chemother; 1988 Jun; 32(6):925-7. PubMed ID: 2843088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity of AVE1330A, an innovative broad-spectrum non-beta-lactam beta-lactamase inhibitor.
    Bonnefoy A; Dupuis-Hamelin C; Steier V; Delachaume C; Seys C; Stachyra T; Fairley M; Guitton M; Lampilas M
    J Antimicrob Chemother; 2004 Aug; 54(2):410-7. PubMed ID: 15254025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sulbactam: biochemical factors involved in its synergy with ampicillin.
    Labia R; Morand A; Lelievre V; Mattioni D; Kazmierczak A
    Rev Infect Dis; 1986; 8 Suppl 5():S496-502. PubMed ID: 3025996
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fixed or variable concentrations of beta-lactamase inhibitors in in-vitro tests?
    Greenwood D
    J Antimicrob Chemother; 1996 Jul; 38(1):17-20. PubMed ID: 8858452
    [No Abstract]   [Full Text] [Related]  

  • 37. Characterization of a PSE-4 mutant with different properties in relation to penicillanic acid sulfones: importance of residues 216 to 218 in class A beta-lactamases.
    Sabbagh Y; Thériault E; Sanschagrin F; Voyer N; Palzkill T; Levesque RC
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2319-25. PubMed ID: 9736556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Piperacillin tazobactam compared with co-amoxiclav, ampicillin plus sulbactam and timentin against beta-lactamase-producing clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca.
    Traub WH; Leonhard B
    Chemotherapy; 1995; 41(5):345-52. PubMed ID: 8521736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative in-vitro activities of GD-40 and other beta-lactamase inhibitors against TEM-1 and SHV-2 beta-lactamases.
    Danelon G; Mascaretti O; Radice M; Power P; Calcagno ML; Mata EG; Gutkind G
    J Antimicrob Chemother; 1998 Feb; 41(2):313-5. PubMed ID: 9533481
    [No Abstract]   [Full Text] [Related]  

  • 40. Activity of beta-lactamase inhibitors in combination with new beta-lactam antibiotics against resistant gram-negative organisms.
    Bolivar R; Weaver SS; Bodey GP
    Diagn Microbiol Infect Dis; 1984 Jun; 2(3):255-60. PubMed ID: 6086213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.